<html xmlns="http://www.w3.org/1999/xhtml"><body><table class="table"><caption /><tr><th class="cell">Study </th><th class="cell">Category of risk factor reported </th><th class="cell">Data source of study </th><th class="cell">Sample size of study (N) </th><th class="cell">Risk factor details </th></tr><tr><td class="cell">Argyriou (2013)</td><td class="cell">Genetic</td><td class="cell">Prospective cohort</td><td class="cell">200</td><td class="cell">SNC4A-rs2302237 OR = 2.65 (1.15–6)</td></tr><tr><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="cell">SCN10A-rs1263292 OR = 0.39 (0.17–0.88)</td></tr><tr><td class="cell">Attal (2009)</td><td class="cell">Clinical</td><td class="cell">Prospective cohort</td><td class="cell">18</td><td class="cell">Cold allodynia OR = 39 (1.8–817)</td></tr><tr><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="cell">Cold hyperalgesia OR = 3.9 (1.0–1.20)</td></tr><tr><td class="cell">Baldwin (2012)</td><td class="cell">Genetic</td><td class="cell">Prospective cohort</td><td class="cell">855</td><td class="cell">FGD4-rs10771973 HR = 1.57 (1.30–1.91)</td></tr><tr><td class="cell">Dimopoulos (2011)</td><td class="cell">Clinical</td><td class="cell">RCT</td><td class="cell">340</td><td class="cell">Baseline neuropathy HR = 1.79 (p &lt; 0.01)</td></tr><tr><td class="cell">Glendenning (2010)</td><td class="cell">Clinical and treatment-related</td><td class="cell">Cross-sectional cohort</td><td class="cell">293</td><td class="cell">Cisplatin dose increase OR = 1.91 (1.61–2.26)</td></tr><tr><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="cell">Carboplatin dose increase OR = 1.26 (1.04–1.52)</td></tr><tr><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="cell">Age at follow-up OR = 1.06 (1.04–1.08)</td></tr><tr><td class="cell">Johnson (2011) ^{⁄}</td><td class="cell">Genetic</td><td class="cell">RCT</td><td class="cell">970 + 550</td><td class="cell">ABCA1-rs363717 OR = 0.71 (0.52–0.98)</td></tr><tr><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="cell">ICAM1-rs1799969 OR = 0.67 (0.44–1.03)</td></tr><tr><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="cell">PPARD-rs2076169 OR = 0.60 (0.38–095)</td></tr><tr><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="cell">SERPINB2-rs6103 OR = 0.70 (0.52–0.95)</td></tr><tr><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="cell">SLC12A6-rs7164902 OR = 0.60 (0.44–0.80)</td></tr><tr><td class="cell">Kawakami (2012)</td><td class="cell">Clinical</td><td class="cell">Prospective cohort</td><td class="cell">50</td><td class="cell">Smoking history pack-years HR = 1.03 (1.0–1.05)</td></tr><tr><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="cell">Decreased creatinine clearance HR = 0.96 (0.92–0.99)</td></tr><tr><td class="cell">Won (2012) ^{†}</td><td class="cell">Genetic</td><td class="cell">Prospective cohort</td><td class="cell">96</td><td class="cell">TAC1-rs10486003</td></tr><tr><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="cell">FOXC1-rs2338</td></tr><tr><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="cell">ITGA1-rs830884</td></tr><tr><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="cell">ACYP2-rs843748</td></tr><tr><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="empty"></td><td class="cell">DLEU7-rs797519</td></tr></table></body></html>